Skip to content
value.today

Ardelyx, Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value

Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.

Price to salesPrice to sales of Biotechnology: $917 M to $4.1 B, median $2.0 BPrice to bookPrice to book of Biotechnology: $511 M to $2.2 B, median $750 M$0 M$1.1 B$2.2 B$3.3 B$4.5 BMarket value $822 M

Your own DCF model

A full discounted-cash-flow model of Ardelyx, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Biotechnology

Multiples of its companies with a market value at most 60 days old, times Ardelyx, Inc.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)Ardelyx, Inc.Applied toValue (25th to 75th)Companies
Price to sales2.3× / 5.0× / 10.2×1.8×revenue $407 M$917 M to $4.1 B84
Price to book3.1× / 4.5× / 12.9×4.9×book equity $167 M$511 M to $2.2 B69

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

Against its own history

Ardelyx, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.

Price to sales

1.8×

Now below its median of 3.7×, in the bottom quarter of its range; range 1.8× to 185.1× over 30 months.

0×46×93×139×185×2020202120222023202420252026Price to sales 2×Median 4×

Price to book

4.9×

Now below its median of 7.5×, in the bottom quarter of its range; range 0.9× to 14.5× over 30 months.

0×4×7×11×15×2020202120222023202420252026Price to book 5×Median 8×

as of Oct 9, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 9, 2026.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025$407 M$-62 M$-42 M$1 M$-44 M$135 MSEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024$334 M$-39 M$-45 M$1 M$-46 M$86 MSEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023$124 M$-66 M$-90 M$0 M$-90 M$28 MSEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$52 M$-67 M$-70 M$0 M$-70 M$-69 MSEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$10 M$-158 M$-153 M$2 M$-154 M$-40 MSEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$8 M$-94 M$-81 M$0 M$-82 M$-40 MSEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value $822 M on Oct 9, 2026.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.